News | Oncology Related Products | May 06, 2016

Study Finds Breast Cancer Adjuvant Therapy Benefits Vary Over Time

Therapies completed years ago may not keep covering survivors

breast cancer, adjuvant therapy, clinical study, University of Texas Health Science Center

May 6, 2016 — After breast cancer surgery, women are prescribed adjuvant (or follow-up) therapies such as chemotherapy and endocrine drugs to reduce the risk of the cancer returning. It's been assumed that the treatment effects of these therapies remain constant over time, but a new study from the Cancer Therapy & Research Center (CTRC) at The University of Texas Health Science Center at San Antonio suggests the opposite is true.

The study, published in the Journal of the National Cancer Institute, looked at 19 breast cancer adjuvant therapy clinical trials of the National Surgical Adjuvant Breast and Bowel Project (NSABP). Therapies were evaluated for relative benefit, defined as the percentage by which they reduced recurrence and death among study participants.

Researchers found time-varying treatment effects of adjuvant therapies in nearly half of the trials (nine of 19). "In some trials, the benefit diminished at specific points of time after surgery," said study senior author Ismail Jatoi, M.D., Ph.D., FACS. "In other trials, there was no benefit early on, but then there was a delayed benefit that emerged more than one year after surgery."

In one clinical trial, the researchers found that a regimen provided initial benefit, but then a subsequent disadvantage, to patients, he said. Jatoi is the Dale H. Dorn Chair in Surgery in the School of Medicine at the UT Health Science Center, and serves as professor and chief of the Division of Surgical Oncology and Endocrine Surgery.

The findings may change the way oncologists talk to their patients about effects of treatments they are receiving, Jatoi said.

"We are seeing more and more long-term survivors of breast cancer who had these treatments many years ago," he said. "The question is, if these treatment effects have waned, should we consider extended adjuvant treatment regimens for the long term in some patients."

Adjuvant therapy trials should be designed and interpreted with this in mind, he added.

In 2011, Jatoi wrote a viewpoint article published in the Journal of Clinical Oncology in which he proposed that treatment effects of adjuvant therapy regimens might vary over time. He approached the NSABP, one of the nation's largest clinical trials groups, about doing a study.

NSABP statisticians Hanna Bandos, Ph.D., and Jong Hyeon Jeong, Ph.D., conducted much of the work and are co-authors of the study.

For more information: www.jnci.oxfordjournals.org

Related Content

Fujifilm Announces Nationwide Breast Health Campaign With Mobile Mammography Coach

At the center of the campaign, Fujifilm will be traveling around the U.S. with its "Aspire to Be Fearless" mobile mammography coach to provide educational opportunities for clinicians, raise awareness about the importance of screening and will be providing mammograms to the underserved population in key locations.

News | Mammography | June 14, 2019
Fujifilm Medical Systems U.S.A. Inc. announced a nationwide awareness campaign titled ‘Aspire to Be Fearless’ focused...
Ikonopedia Showcases Risk Assessment and Resolution Manager Tools at SIIM and AHRA
News | Mammography Reporting Software | June 13, 2019
Ikonopedia will showcase its suite of structured breast reporting and Mammography Quality Standards Act (MQSA)...
Sponsored Content | Videos | Radiology Imaging | June 13, 2019
In an interview with itnTV, Henry Izawa, vice president, modality solutions and clinical affairs, Fujifilm Medical Sy
iCAD Introduces ProFound AI for 2D Mammography in Europe
News | Artificial Intelligence | June 13, 2019
iCAD Inc. announced the launch of ProFound AI for 2D Mammography in Europe. This software is the latest addition to...
Three Palm Software Releases WorkstationOne Version 1.8.8
Technology | Mammography Reporting Software | June 12, 2019
Three Palm Software announced the release of the 1.8.8 version of its breast imaging workstation, WorkstationOne. This...
Volpara Health Technologies to Acquire MRS Systems Inc.
News | Mammography Reporting Software | June 04, 2019
Volpara Health Technologies, Volpara Solutions' parent company, has signed a binding agreement to acquire U.S.-based...
62-year-old female patient presenting for 3D screening mammogram. Location of an indeterminate low-density circumscribed mass was not clearly determined as at the skin line or just under the surface.

62-year-old female patient presenting for 3D screening mammogram. Location of an indeterminate low-density circumscribed mass was not clearly determined as at the skin line or just under the surface.

Feature | Mammography | May 31, 2019 | By Olive Peart M.S., R.T.(R)(M)
In recent years there has been a lot of debate about the role of the...
Quantitative Transmission Ultrasound Featured at Acoustical Society of America

Fused QT Ultrasound 3-D quantitative transmission ultrasound and compounded reflection axial images showing high resolution image of internal organs, tissue, skin and hair of neo-natal piglet. Anatomy courtesy of C. Ruoff, DVM.

News | Ultrasound Imaging | May 29, 2019
May 29, 2019 — QT Ultrasound recently showcased its advanced...
VolparaDensity With Tyrer-Cuzick Model Improves Breast Cancer Risk Stratification
News | Breast Density | May 22, 2019
Research has demonstrated use of Volpara Solutions' VolparaDensity software in combination with the Tyrer-Cuzick Breast...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...